Manogepix (E1210) is an pyridine-isoxazole-based broad-spectrum antifungal.[1] Manogepix targets an enzyme involved in the post-translational modification of fungal proteins.
Clinical data | |
---|---|
Other names | E1210, APX001A |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C12H18N4O2 |
Molar mass | 250.302 g·mol−1 |
3D model (JSmol) | |
| |
|
Manogepix is the active metabolite of the prodrug fosmanogepix.[2]
References
edit- ^ Pfaller MA, Hata K, Jones RN, Messer SA, Moet GJ, Castanheira M (October 2011). "In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method". Diagnostic Microbiology and Infectious Disease. 71 (2): 167–170. doi:10.1016/j.diagmicrobio.2011.05.001. PMID 21696907.
- ^ Badali H, Patterson HP, Sanders CJ, Mermella B, Gibas CF, Ibrahim AS, et al. (May 2021). "Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates In Vitro Activity against Members of the Fusarium oxysporum and Fusarium solani Species Complexes". Antimicrobial Agents and Chemotherapy. 65 (6). doi:10.1128/AAC.02343-20. PMC 8315997. PMID 33722886.